Celgene (CELG) Tops Q4 EPS by 7c, Offers FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. TPR

January 31, 2019 7:32 AM EST

Celgene (NASDAQ: CELG) reported Q4 EPS of $2.39, $0.07 better than the analyst estimate of $2.32. Revenue for the quarter came in at $4.04 billion versus the consensus estimate of $3.99 billion.

Volume-Driven Product Sales and Earnings Growth Expected in 2019

����2019 Guidance���Year-over-Year Change
Total Revenue���$17.0B to $17.2B���~12%*
REVLIMID® Net Product Sales ~ $10.8B ~12%
POMALYST®/IMNOVID® Net Product Sales ~ $2.4B ~18%
OTEZLA® Net Product Sales ~ $1.9B ~18%
ABRAXANE® Net Product Sales ~ $1.1B ~4%
GAAP Operating Margin** Approximately 49% N/M**
Adjusted Operating Margin Approximately 57.5% ~+200 bps
Adjusted Tax Rate ~17.0% ~+50 bps
GAAP diluted EPS $8.40 - $9.08 N/M**
Adjusted diluted EPS $10.60 - $10.80 ~21%*
Weighted average diluted shares ~715M ~(20M)

*Year-over-year percentage change based on the mid-point of the range.

(**Street sees FY EPS of $10.42 on revenue of $17 billion)

For earnings history and earnings-related data on Celgene (CELG) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings